key: cord-0807238-fzp11ut0
authors: Sakamaki, I.; Morinaga, Y.; Tani, H.; Takegoshi, Y.; Fukui, Y.; Kawasuji, H.; Ueno, A.; Miyajima, Y.; Wakasugi, M.; Kawagishi, T.; Kuwano, H.; Hatano, T.; Shibuya, T.; Okudera, H.; Yamamoto, Y.
title: Monitoring of viral load by RT-PCR caused decision making to continue ECMO therapy for a patient with COVID-19
date: 2020-08-20
journal: J Infect Chemother
DOI: 10.1016/j.jiac.2020.08.014
sha: 2a2a4a929a8dee138b8ff5c10f7ffa913e945fb2
doc_id: 807238
cord_uid: fzp11ut0

Abstract Most patients with coronavirus disease 2019 (COVID-19) have just only mild symptoms, but about 5% are very severe. Although extracorporeal membranous oxygenation (ECMO) is sometimes used in critically patients with COVID-19, ECMO is only an adjunct, not the main treatment. If the patient's condition deteriorates and it is determined to be irreversible, it is necessary to decide to stop ECMO. A 54-year-old man was admitted on day 6 of onset with a chief complaint of high fever and cough. Computed tomography (CT) showed a ground glass opacity in both lungs, and reverse transcription-polymerase chain reaction (RT-PCR) diagnosed COVID-19. He was admitted to the hospital and started to receive oxygen and favipiravir. After that, his respiratory condition deteriorated, and he was intubated and ventilated on day 9 of onset, and ECMO was introduced on day 12. Two days after the introduction of ECMO, C-reactive protein (CRP) increased, chest X-p showed no improvement in pneumonia, and PaO2/FiO2 decreased again. As D-dimer rose and found a blood clot in the ECMO circuit, we had to decide whether to replace the circuit and continue with ECMO or stop ECMO. At this time, the viral load by RT-PCR was drastically reduced to about 1/1750. We decided to continue ECMO therapy and replaced the circuit. The patient's respiratory status subsequently improved and ECMO was stopped on day 21 of onset. In conclusion, viral load measurement by RT-PCR may be one of the indicators for promoting the treatment of severe COVID-19 patients.

From the end of 2019, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread to the world. Most patients with COVID-19 have just only mild symptoms, but about 5% are critical (1, 2) . There are several reports of using extracorporeal membranous oxygenation (ECMO) in severe cases. In an early report from China, 4 out of 138 (2.9%) inpatients needed ECMO. (3) Another group reported that 3% of patients received ECMO. (4) Other teams in China reported that 11.5% of COVID-19 cases in the intensive care unit (ICU) received ECMO as rescue therapy. (5) It is not easy to judge the ECMO indication. In addition to making decisions about each patient's indications, we must consider the appropriate allocation of socially limited medical resources.

Although there are some guidelines, it is difficult to select the patients and the timing of ECMO initiation and to manage monitoring and weaning of ECMO. The most difficult thing is the decision to discontinue ECMO if we could not save the patient. Here we present a COVID-19 case that we decided to continue ECMO using the viral load by RT-PCR as an index.

J o u r n a l P r e -p r o o f

The case was a 54-years-old man who had a cough and high fever of 39 degrees or higher on day 0. On day 1, he met a primary care doctor and started to take 500 mg/day azithromycin. But his symptom did not improve.

He came to our hospital on day 6. On physical examination, his vital signs were as follows: blood pressure, 102/78 mmHg; pulse, 96/min; respiratory rate, 32/min; oxygen saturation, 92% on room air; body temperature, 39.2 °C; and Glasgow Coma Scale (GCS), 15. White blood count (WBC) was 2650/µL (Neutro 72.4%, Lymph 23.4%), C-reactive protein (CRP) was 3.12 mg/mL. D-dimer was 1.3 µg/mL (normal range < 1 µg/mL). His computed tomography (CT) images showed ground glass opacity on both lungs (Fig 1) . RT-PCR test of the nasal specimen showed the positive result of SARS-CoV-2.

He admitted to the ICU and received non-invasive ventilation. Also, he started to take an anti-viral agent, Favipiravir. But, because his respiratory condition was worse sharply on day 9, he needed intubation and invasive mechanical ventilation. The respiratory status worsened further and bilateral pneumonia on the chest X-ray also worsened (Fig. 2) . ECMO was introduced on day 12. Furthermore, his renal function worsened, continuous hemodiafiltration (CHDF) was also introduced on day 13. His J o u r n a l P r e -p r o o f condition did not improve immediately after the ECMO introduction. PaO 2 /FiO 2 had increased temporally but decreased again (Fig. 3) . CRP increased to 32.42 mg/dL. There was a coagulation abnormality. Clots were found in the circuit of ECMO, and D-dimer increased to over 30 µg/mL. Thus, we had to decide whether to make a circuit switch and continue ECMO, or stop ECMO. At that time, the RT-PCR test of nasopharyngeal swab samples still showed positive. However, the viral load decreased from 8.33×10 4 copies/µL (day 6) to 4.80×10 copies/µL (day 14). Viral road decreased to about 1/1750 compared to that on admission. We decided to continue the ECMO therapy and replace the circuit of the ECMO (day 15). After that, the patient's condition improved and pneumonia improved on chest X-ray (Fig. 2) . ECMO and CHDF were terminated on day 21. RT-PCR of nasal specimen showed a negative result. (Fig. 3) Favipiravir was administered 3600 mg/day on day 6 and 1600 mg/day from day 7 to day 19 for a total of 14 days. A respirator was not needed on day 24 and the patients moved to the general ward from ICU on day 29. Coagulopathy may associate with the severity of COVID-19 patients.

In our case, clots were found in the circuit and the patient's D-dimer increased to over 30 mg/mL immediately after the introduction of ECMO. PaO 2 /FiO 2 was decreased to less than 100 mmHg and CRP increased to over 30 mg/dL. Coagulopathy might be due to the placement of the cannulas for ECMO. We judged that the patient's condition was very severe. We needed to decide to stop ECMO or to replace the circuit and continue ECMO. Viral load by RT-PCR of nasal specimen decreased to about 1/1750 at that time, we could decide to continue ECMO and replaced the circuit.

RT-PCR is now generally used to detect SARS-CoV-2 or confirm negative for SARS-CoV-2. The result of the RT-PCR test shows usually just positive or negative, viral load is not shown. One of the papers about viral load showed that the viral load early after onset was high, but a sputum sample collected on day 8 post-onset from a patient who died had a very high viral load (12). Another report revealed that viral loads in mild cases decreased, while viral loads in severe cases did not change or increased (13). Patients in our hospital showed that viral loads of symptomatic patients were higher than those of asymptomatic patients (14). If the persistently high viral load in patients with COVID-19 could lead to severe disease; preparation for invasive ventilation and ECMO therapy may be necessary.

For determining the severity of COVID-19, it is better to use a blood sample to accurately measure the viral load. However, it has been reported that RNAemia was only found in patients with critical COVID-19 (15). Nasopharyngeal swab samples are usually used for initial RT-PCR testing, and we use nasal specimens to see changes in We should evaluate the clinical advantages of viral loads-guided monitoring because it can be useful for planning the management of asymptomatic carriers as well as patients.

In conclusion, viral load measurement by RT-PCR of nasopharyngeal swab samples can be one of the indicators for management of COVID-19 patients.

J o u r n a l P r e -p r o o f

The administration of Favipiravir and RT-PCR tests as clinical studies were approved by the Ethics Committee of the Toyama University Hospital. Written informed consent was obtained from the patient for publication of this case report.

None.

No funding for this study.

IS, YM, HO and YY contributed to study design, data collection and writing the report. 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study

Surviving Sepsis Campaign: Guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)

World Health Organization. Clinical management of severe acute respiratory infection when COVID-19 is suspected. Interim guidance

(ncov)-infection-is-suspected

Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe Card

High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicentre prospective cohort study

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study